| Proteomics: translating genomics into products? A Dove Nature biotechnology 17 (3), 233-236, 1999 | 260 | 1999 |
| The bittersweet promise of glycobiology A Dove Nature biotechnology 19 (10), 913-917, 2001 | 230 | 2001 |
| Uncorking the biomanufacturing bottleneck A Dove Nature biotechnology 20 (8), 777-779, 2002 | 133 | 2002 |
| Cell-based therapies go live A Dove Nature biotechnology 20 (4), 339-343, 2002 | 126 | 2002 |
| Drug screening—beyond the bottleneck A Dove Nature biotechnology 17 (9), 859-863, 1999 | 125 | 1999 |
| Screening for content—the evolution of high throughput A Dove Nature biotechnology 21 (8), 859-864, 2003 | 111 | 2003 |
| Antisense and sensibility A Dove Nature biotechnology 20 (2), 121-124, 2002 | 106 | 2002 |
| MMP inhibitors: glimmers of hope amidst clinical failures CM Cher Nature medicine 8 (2), 95, 2002 | 67 | 2002 |
| CD18 trials disappoint again A Dove Nature biotechnology 18 (8), 817-818, 2000 | 67 | 2000 |
| The polio eradication effort: should vaccine eradication be next? AW Dove, VR Racaniello Science 277 (5327), 779-780, 1997 | 63 | 1997 |
| Cold-adapted poliovirus mutants bypass a postentry replication block AW Dove, VR Racaniello Journal of virology 71 (6), 4728-4735, 1997 | 63 | 1997 |
| Milking the genome for profit A Dove Nature biotechnology 18 (10), 1045-1048, 2000 | 60 | 2000 |
| An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures AW Dove, VR Racaniello Journal of virology 74 (8), 3929-3931, 2000 | 35 | 2000 |
| From bits to bases: Computing with DNA A Dove Nature Biotechnology 16 (9), 830-832, 1998 | 27 | 1998 |
| High-throughput screening goes to school A Dove Nature Methods 4 (6), 523-532, 2007 | 26 | 2007 |
| Breaching the barrier: the blood-brain barrier has confounded the development of many neurological treatments over the years. Now, several companies are claiming they can … A Dove Nature Biotechnology 26 (11), 1213-1216, 2008 | 23 | 2008 |
| News Feature: Drugs down the drain A Dove Nature medicine 12 (4), 376-378, 2006 | 20 | 2006 |
| Survey raises concerns about Bt resistance management. A Dove Nature Biotechnology 19 (4), 293-295, 2001 | 20 | 2001 |
| Betting on biogenerics A Dove Nature biotechnology 19 (2), 117-120, 2001 | 19 | 2001 |
| Making a living out of the art of dying A Dove Nature biotechnology 19 (7), 615-619, 2001 | 17 | 2001 |
